Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 11:04 AM ET
Aurinia Pharmaceuticals Inc (AUPH) P/E Ratio & Valuation History
Aurinia Pharmaceuticals (AUPH) trades at 15.2x trailing earnings and 6.4x sales. Its P/S of 6.4x is below its 5-year median of 6.9x. Its forward P/E is 11.3x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 34.5% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 15.2x |
| Forward P/E | 11.3x |
| Price to sales | 6.4x |
| Price to book | 3.1x |
| EV/EBITDA | 12.1x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 11.4% below 3.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.4x | 6.9x | N/A |
| P/B | 3.1x | 3.3x | 3.5x |
Valuation History
Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 4.6x in 2022 to 866.0x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $15.95 | 19.7x | 7.7x | 3.8x |
| 2024 | $8.98 | 179.6x | 5.5x | 3.5x |
| 2023 | $8.99 | N/A | 7.3x | 3.4x |
| 2022 | $4.32 | N/A | 4.6x | 1.5x |
| 2021 | $22.87 | N/A | 65.3x | 6.3x |
| 2020 | $13.83 | N/A | 32.7x | 4.0x |
| 2019 | $20.26 | N/A | N/A | 6.6x |
| 2018 | $6.82 | N/A | N/A | 5.2x |
| 2017 | $4.53 | N/A | 866.0x | 2.3x |
| 2016 | $2.10 | N/A | 433.6x | 3.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AUPH
What is AUPH's forward P/E ratio?
Aurinia Pharmaceuticals has a forward P/E ratio of 11.3x.
Is AUPH stock overvalued?
GNG's valuation label for AUPH is Undervalued.
What is AUPH's price to sales ratio?
Aurinia Pharmaceuticals has a price to sales ratio of 6.4x.
AUPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors